Variable | (A) Coverage of the organism isolatedΔ(n=156) or (95%C.I.) | (B) Double coverage (n = 804) or (95%C.I.) | (C) Discordant anti-mrsa therapy (n = 181) or (95%C.I.) |
---|---|---|---|
Age group (adult vs. pediatric) | 1.92 (0.78-4.76) | 5.60 (3.39-9.25) | 1.63 (0.82-3.23) |
Infection Location | |||
Hand | Ref. | Ref. | Ref. |
Other extremity | 1.71 (0.45-6.44) | 1.37 (0.87-2.18) | 1.16 (0.41-3.25) |
Buttock | *** | 1.07 (0.55-2.11) | 1.00 (0.28-3.54) |
Trunk | 2.31 (0.5-10.67) | 1.00 (0.56-1.78) | 0.64 (0.22-1.87) |
Head | 0.62 (0.1-3.66) | 1.15 (0.44-2.96) | 4.00 (0.40-39.83) |
Face | 4.92 (0.49-49.61) | 0.95 (0.54-1.68) | 0.46 (0.13-1.59) |
Genitalia | 0.31 (0.02-6.11) | 1.07 (0.30-3.81) | 0.67 (0.04-12.27) |
Multiple Locations | 1.23 (0.11-14.42) | 1.07 (0.45-2.54) | 0.67 (0.08-5.75) |
Previous assessment for this infection | 1.27 (0.4-4.02) | 0.85 (0.60-1.20) | 0.86 (0.42-1.79) |
Previous antibiotic treatment for this infection | 4.13 (0.53-32.28) | 0.81 (0.54-1.22) | 0.45 (0.19-1.07) |
Disposition (hospital admission) | 2.78 (1.12-6.89)* | 0.99 (0.73-1.35) | 0.66 (0.33-1.32) |
I&D performed | 4.47 (1.71-11.65)* | 1.07 (0.77-1.47) | 0.87 (0.47-1.60) |
Culture performed | N/A | 1.37 (1.00-1.87) | N/A |
Gender | |||
Male | Ref. | Ref. | Ref. |
Female | 0.92 (0.38-2.24) | 0.75 (0.56-1.00) | 0.82 (0.45-1.47) |
Ethnicity/race | |||
White | Ref. | Ref. | Ref. |
Black | 1.58 (0.49-5.05) | 0.65 (0.43-0.97)* | 0.89 (0.41-1.89) |
Hispanic/Other | 5.62 (0.71-44.27) | 0.72 (0.48-1.09) | 1.06 (0.46-2.42) |
Health insurance status | |||
Private | Ref. | Ref. | Ref. |
Governmental | 1.31 (0.41-4.19) | 0.94 (0.66-1.34) | 0.85 (0.40-1.77) |
Both private and Governmental | 0.11 (0.02-0.5)* | 0.80 (0.45-1.43) | 1.94 (0.36-10.50) |
None | 1.63 (0.44-5.98) | 1.23 (0.84-1.81) | 0.69 (0.33-1.47) |